BOSTON, April 14, 2011 /PRNewswire/ — BT (NYSE:
BT) shared its vision of the future of pharma R&D and the
application of cloud computing strategies to pharma research at the
Bio-IT World Conference & Expo held this week in Boston. This
vision reflects BT’s strong capabilities and increasing
specialization around a number of industry sectors. Many of the
world’s leading pharmaceutical companies rely on BT to support
their strategy in terms of globalization, operational effectiveness
and innovation cycles.
In a keynote panel session, Yury Rozenman, Global Head of
Marketing, Pharmaceutical and Life Sciences Sector, BT Global
Services, described the pressures currently facing pharma R&D,
as well as the opportunities to improve the R&D and innovation
process by seamlessly connecting partners, suppliers, biotechs,
devices and diagnostic, regulatory agencies and clinical research
organizations in an R&D ecosystem.
Rozenman said: “An R&D innovation ecosystem is essentially a
networked cooperative: the more participants, the greater value;
the more contribution by individual participants, the less expense
to use the ecosystem.”
Rozenman noted that the benefits of embracing the R&D
innovation ecosystem model include increased speed to trial,
leading to savings of millions of dollars per drug, reduced costs
via out-tasking, and more effective collaboration between industry
players and partners, leading to improved research productivity.
The differentiator is the ability to integrate not just data and
applications but the human resources of the global R&D pharma
community.
Leading a session on cloud computing at the same event, Neil
Lock, IT Services Program Director, BT Global Services, examined
the practical aspects of cloud computing as it relates to pharma
R&D.
Lock said: “Much of the debate, hype and headlines about
clo
‘/>”/>
